ADCC-Enhanced Anti-Human CD38 (Felzartamab) Antibody (CAT#: BioBet-CB-031LX) Datasheet

CD38

platelet derived growth factor receptor alpha

This gene encodes a cell surface tyrosine kinase receptor for members of the platelet-derived growth factor family. These growth factors are mitogens for cells of mesenchymal origin. The identity of the growth factor bound to a receptor monomer determines whether the functional receptor is a homodimer or a heterodimer, composed of both platelet-derived growth factor receptor alpha and beta polypeptides. Studies suggest that this gene plays a role in organ development, wound healing, and tumor progression. Mutations in this gene have been associated with idiopathic hypereosinophilic syndrome, somatic and familial gastrointestinal stromal tumors, and a variety of other cancers.

Platelet Derived Growth Factor Receptor Alpha; Platelet-Derived Growth Factor Receptor; Alpha Polypeptide; Alpha-Type Platelet-Derived Growth Factor Receptor; Platelet-Derived Growth Factor Receptor 2; CD140 Antigen-Like Family Member A; CD140a Antigen; PDGF-R-Alpha; EC 2.7.10.1; PDGFR-2;

Cell Biology, Immunology,

Protein Based Therapies
Monoclonal antibody (mAb)

IgG1

Felzartamab

Human

Human

ADCC-Enhanced Anti-Human CD38 (Felzartamab) Antibody is derived from clone Felzartamab, which is a Human monoclonal antibody with enhanced ADCC activity. Antibody-dependent cellular cytotoxicity (ADCC) is an important function of antibody. It is a part of the humoral immune response to limit and contain infection. The antibody targets the CD38, and it is intended for the research of Multiple myeloma .

Multiple myeloma

Similar to the parental antibody Felzartamab, ADCC-Enhanced Anti-Human CD38 (Felzartamab) Antibody targets to the antigen CD38, achieving ADCC-enhanced antibody by reducing fucosylation of the Fc region of parental antibody, leading to an increased binding affinity for the FcyR receptor on immune effector cells.